<a href="https://laohu8.com/S/THAR">Tharimmune Inc.</a> Files Prospectus for $1.74 Million Public Offering of Common Stock and Warrants
Tharimmune Inc., a clinical-stage biotechnology company focused on therapies in immunology and inflammation, has announced the pricing of a registered direct public offering aimed at raising approximately $1.74 million. The offering includes 414,331 shares of Common Stock and 559,910 pre-funded warrants to acquire shares of Common Stock, along with 974,241 warrants to acquire shares of Common Stock at an exercise price of $1.66 per share. The securities are offered at $1.786 per unit, following a Securities Purchase Agreement. A preliminary prospectus supplement and accompanying prospectus have been filed with the U.S. Securities and Exchange Commission $(SEC.UK)$, with a final prospectus supplement to follow. President Street Global, LLC is serving as the exclusive placement agent for the offering, which is expected to close around July 25, 2025, contingent on customary closing conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tharimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-021118), on July 28, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。